Related Experiment Video
Updated: Jun 2, 2026
09:03
Trabecular Meshwork Response to Pressure Elevation in the Living Human Eye
Published on: June 20, 2015
Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review
Rajesh K Rajpal1, Donald Digby, Gerard D'Aversa
1SeeClearly Vision, McLean, Virginia 22102, USA. rrajpal@seeclearly.com
Summary
Topical loteprednol etabonate can cause significant intraocular pressure (IOP) elevations, particularly with long-term use. Consider alternatives for chronic ocular surface conditions to manage IOP risks.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Ocular corticosteroids are frequently used for various eye conditions.
- These medications carry a risk of elevating intraocular pressure (IOP).
Purpose of the Study:
- To analyze the timing and severity of IOP elevations in patients using loteprednol etabonate 0.5% or loteprednol etabonate 0.5%/tobramycin 0.3%.
Main Methods:
- Retrospective chart review across 5 clinical practices.
- Included patients with IOP elevation ≥5 mm Hg while on study medications.
- Collected data on demographics, history, IOP, and treatments.
Main Results:
- Fifty patients showed IOP elevations; mean age 58.8 years, 66% female.
- Common indications: dry eye (30%), post-op (22%), allergic conjunctivitis (16%).
- Mean IOP increased from 15.5 to 24.7 mm Hg (avg. increase 9.2 mm Hg) over a median of 55 days; 24% needed IOP-lowering meds, 8% required surgery.
Conclusions:
- Loteprednol etabonate can lead to significant IOP increases.
- Long-term use necessitates careful IOP monitoring.
- Alternatives to corticosteroids may be warranted for chronic ocular surface diseases.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...